Clinical Trial Update: Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL [Phase 2]

View source ↗

Summary

Phase 2 study evaluating bendamustine, lenalidomide, and rituximab as second-line therapy for first-relapsed/refractory mantle cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED